Link maker

FDA shelves Paul Hudson’s $3.7 billion MS drug after linking it to liver damage – Endpoints News

On Tuesday, June 14, Endpoints News EIC John Carroll sat down with a group of biotech executives to discuss the bear market in the industry’s stocks and how they were dealing with it. Here is the conversation, slightly edited for brevity.

Martin Meeson, Opening Sponsor:

Thanks, John. Hi there. My name is Martin Meeson, I am the CEO of Fujifilm Diosynth. For those of you unfamiliar with Fujifilm Diosynth, we operate in large scale clinical and commercial product development, we have facilities in Europe and the United States and approximately 4,000 employees. We manage about 150 programs on average, so when it comes to managing turbulent times over the past two years, we have a lot of experience in this area. Not only keeping clinical pipelines and commercial pipelines open, but also our response to the pandemic and the molecules that we had in there. One of the phrases I coined probably about a year ago when we were talking at JP Morgan was that I was talking about managing in turbulent times. Well, it became the fact that we don’t manage or lead these times, we manage in them, so that’s really the purpose and the subject we have today.

Premium subscription required

Unlock this item and other benefits by subscribing to one of our paid plans.